ICH
ICH Q7 19.40
19. AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS, AND RELABELLERS
조항 원문
Raw materials used in production of APIs for use in clinical trials should be evaluated by testing, or received with a supplier’s analysis and subjected to identity testing. When a material is considered hazardous, a supplier's analysis should suffice.
본문은 원문(영어)입니다. 국문 번역은 준비 중입니다.
출처: International Council for Harmonisation (ICH) · © ICH. Per the legal notice in each guideline, the document may be used, reproduced and distributed provided ICH's copyright is acknowledged; any adaptation or translation must be labelled as such and must not imply ICH endorsement. · 수집일 2026-11-15